Gemcitabine/Abraxane treatment monitoring by 3D bSSFP imaging with hyperpolarized [1-13C]pyruvate in a murine endogenous model of PDAC
Anna-Maria Schmidmüller1, Irina Heid1, Jason G. Skinner2, Geoffrey J. Topping2, Katja Steiger3,5, Simon Baller1, Wolfgang Gottwald2, Franz Schilling2, Rickmer Braren1,4Link to the paper
Research Area C6
Pancreatic ductal adenocarcinoma (PDAC) is a highly heterogeneous disease with poor prognosis and a high mortality rate1. Due to early metastatic spread, most PDAC patients are not eligible for surgery and instead receive palliative chemotherapy-based treatment. Here, we aim to examine changes in tumor metabolism caused by Gemcitabine/Abraxane, a standard of care, using a complex endogenous murine
PDAC model2 and a 3D balanced steady-state free precession (bSSFP)3 MR imaging of hyperpolarized (HP)v[1-13C]pyruvate and its metabolite [1-13C]lactate.